Active Filter(s):
Details:
Under the terms of the agreement, Faran will receive the exclusive rights to market Firibastat for the treatment of difficult-to-treat / resistant hypertension in Greece.
Lead Product(s): Firibastat
Therapeutic Area: Cardiology/Vascular Diseases Product Name: QGC001
Highest Development Status: Phase III Product Type: Small molecule
Recipient: Quantum Genomics
Deal Size: Undisclosed Upfront Cash: $12.1 million
Deal Type: Collaboration December 15, 2020